A Safety Run-In/Randomized Phase II Trial Of EMD 121974 In Conjunction With Concomitant Temozolomide and Adjuvant Temozolomide With Radiation Therapy In Patients With Newly Diagnosed Glioblastoma Multiforme.

Trial Profile

A Safety Run-In/Randomized Phase II Trial Of EMD 121974 In Conjunction With Concomitant Temozolomide and Adjuvant Temozolomide With Radiation Therapy In Patients With Newly Diagnosed Glioblastoma Multiforme.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 29 Feb 2016

At a glance

  • Drugs Cilengitide (Primary) ; Temozolomide
  • Indications Astrocytoma; Glioblastoma
  • Focus Adverse reactions; Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 27 Apr 2012 Actual end date changed from May 2011 to March 2012 as reported by ClinicalTrials.gov.
    • 27 Apr 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 02 Jun 2009 Interim results were presented at ASCO 2009.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top